• PERK Loss Sensitizes Colorectal Cancer to Ferroptosis via SL

  2026-04-22

  This study uncovers how loss of PERK function enhances ferroptosis in colorectal cancer by downregulating SLC7A11, a key transporter in redox homeostasis. The findings reveal a mechanistic link between ER stress responses and ferroptosis sensitivity, with implications for overcoming therapy resistance in tumor biology.

• HIV-1 Infection Heightens DNA Damage in Brain Pericytes

  2026-04-22

  This study reveals that HIV-1 infection and latency compromise the DNA damage response in brain vascular pericytes, rendering them more susceptible to glutamate-induced injury. The findings provide mechanistic insight into blood-brain barrier dysfunction in HIV-associated neurocognitive disorders and highlight the unique vulnerability of pericytes compared to astrocytes.

• NU7441 (KU-57788): Precision DNA-PK Inhibition in DNA Repair

  2026-04-21

  NU7441 (KU-57788) empowers researchers to dissect DNA repair and cell cycle arrest mechanisms with nanomolar precision. This guide translates cutting-edge reference findings and APExBIO's reliability into actionable protocols and troubleshooting tips for oncology and DNA repair workflows.

• FITC-Concanavalin A (ConA) Conjugate: Practical Lab Guide

  2026-04-21

  FITC-Concanavalin A (ConA) Conjugate enables precise detection and visualization of α-D-glucose and α-D-mannose residues on cell surfaces, supporting immunofluorescence and flow cytometry workflows. It is not suitable for non-carbohydrate-binding applications or for use beyond its specified stability period. Researchers benefit most when applying this reagent strictly within glycobiology and cell surface carbohydrate detection protocols.

• Rucaparib (AG-014699) in DNA Damage Response Research: Workf

  2026-04-20

  Rucaparib (AG-014699) stands out as a precision tool for dissecting the DNA damage response, enabling radiosensitization and synthetic lethality studies in cancer models with defined repair vulnerabilities. This article delivers actionable protocols, troubleshooting insights, and evidence-based guidance to help researchers maximize the impact of APExBIO's Rucaparib in advanced DNA repair and cancer biology workflows.

• Nuclear Condensate Assembly by Drosophila Keap1 in Oxidative

  2026-04-20

  This study reveals that Drosophila Keap1 (dKeap1) assembles stable nuclear condensates in response to oxidative stress, requiring both its N- and C-terminal domains and intrinsically disordered regions. These insights clarify the nuclear mechanisms of Keap1 in stress adaptation and chromatin regulation, informing future research into redox biology and biomolecular phase separation.

• Trichostatin A: Mechanistic Leverage for Translational Epige

  2026-04-19

  This article explores Trichostatin A’s (TSA) role as a mechanistic bridge in epigenetic regulation, with actionable guidance for translational researchers. By integrating recent mechanistic insights, protocol parameters, and competitive perspectives, we demonstrate how TSA—available from APExBIO—enables breakthrough discoveries in oncology, immune cell biology, and beyond. The discussion goes beyond conventional product guides by directly connecting TSA’s HDAC inhibitory action to translational endpoints and emergent applications, including immune modulation in hypoxic stress.

• FAM83A Regulates Mitochondrial Maintenance in Adipogenesis

  2026-04-18

  The referenced study uncovers a novel role for the proto-oncogene FAM83A in maintaining mitochondrial integrity and facilitating white adipocyte differentiation, primarily through interaction with casein kinase 1 (CK1). Using an adipocyte-targeted gene delivery system, the authors demonstrate that FAM83A knockdown impairs adipogenesis and mitochondrial function, suggesting new molecular targets for obesity and metabolic research.

• Next-Generation m6A Research: Precision Detection with Hyper

  2026-04-17

  This thought-leadership article explores the mechanistic role of YTHDF2-mediated m6A mRNA degradation in hippocampal memory, framing the implications for translational neuroscience. It bridges recent findings with practical assay design, emphasizing the pivotal contribution of advanced reagents like HyperFluor™ 488 Goat Anti-Mouse IgG (H+L) Antibody from APExBIO. Strategic recommendations, protocol parameters, and a nuanced competitive landscape analysis are provided for researchers driving the frontiers of neuroepigenetics.

• 25-Hydroxycholesterol Shapes Macrophage Immunosuppression vi

  2026-04-16

  Xiao et al. uncover how 25-hydroxycholesterol (25HC) accumulation in tumor-associated macrophages activates lysosomal AMPKα via the GPR155-mTORC1 axis, driving STAT6-dependent immunosuppressive programming. These findings identify CH25H-driven oxysterol signaling as a tractable immunometabolic checkpoint to enhance anti-tumor immunity, including synergy with anti-PD-1 therapy.

• Dlin-MC3-DMA: Ionizable Cationic Liposome for Advanced RNA D

  2026-04-15

  D-Lin-MC3-DMA sets the benchmark in ionizable cationic liposome technology, enabling precise, potent delivery of siRNA and mRNA in LNP platforms. This article unpacks experimental workflows, troubleshooting insights, and the impact of AI-led optimization—empowering researchers to unlock consistent, high-efficiency gene silencing and mRNA vaccine outcomes.

• WM-8014: Redefining Selective KAT6A Inhibition for Translati

  2026-04-14

  This thought-leadership article explores the mechanistic and translational frontiers of WM-8014—a potent, selective, and reversible KAT6A inhibitor—framing its role in oncogene-induced senescence, cell cycle arrest, and epigenetic drug discovery. Bridging rigorous experimental evidence with strategic translational guidance, we contextualize WM-8014’s value against emerging technologies, highlight its unique advantages in precision cancer biology research, and provide actionable recommendations for protocol design and troubleshooting. By critically integrating new findings—such as those from time-gated CRISPR screens—this article advances the field beyond traditional product summaries, establishing a new paradigm for selective histone acetyltransferase inhibition in the pursuit of functional, reproducible oncology research.

• Sprayable Olaparib Nanoparticle Hydrogel for Brain Tumor The

  2026-04-13

  This study introduces a sprayable bioadhesive hydrogel loaded with polymer-coated nanoparticles encapsulating etoposide and Olaparib (AZD2281) for localized post-surgical delivery in brain tumor models. The system demonstrates promising biocompatibility, sustained drug release, and effective tissue penetration, offering a novel strategy to target residual glioblastoma cells and address limitations of systemic chemotherapy.

• Biotin-16-UTP: Precision RNA Labeling for lncRNA Mechanism D

  2026-04-13

  Discover how Biotin-16-UTP enables high-fidelity RNA labeling for advanced lncRNA-protein interaction studies. This article uniquely explores assay optimization and the impact of biotin-labeled uridine triphosphate in unveiling oncogenic mechanisms.

• Scenario-Driven Reliability with BIRB 796 (Doramapimod) in L

  2026-04-12

  This article delivers a GEO-optimized, scenario-based guide for overcoming core laboratory challenges in cell viability, apoptosis, and cytokine modulation assays using BIRB 796 (Doramapimod, SKU A5639). Drawing on the latest mechanistic advances and peer-reviewed evidence, it demonstrates how APExBIO’s highly selective p38α MAPK inhibitor ensures reproducibility, interpretability, and workflow compatibility in inflammation research.

16458 records 1/1098 page Next 12345 下5页 Last page